세계의 건조 분말 흡입기 시장 예측(-2030년) : 제품별, 기능별, 적응증별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Dry Powder Inhalers Market is accounted for $21.48 billion in 2023 and is expected to reach $33.60 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dry powder inhalers are medical devices that inhale powdered medication directly into the lungs. For the treatment of lung-related disorders and respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), they are frequently prescribed. They don't need propellants to deliver the medication, in contrast to metered-dose inhalers (MDIs) and are also appropriate for people who might have trouble using MDIs because they do not require hand-breath coordination.

According to the article titled "Common Respiratory Disorders" published in April 2020 around 15% of older adults from asthma, chronic obstructive pulmonary disease, or another respiratory disorder.

Market Dynamics:

Driver:

Rising prevalence of respiratory disorders

The increasing prevalence of respiratory ailments such as cystic fibrosis, bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) directly drives the need for efficient inhalation therapies. Since dry powder inhalers provide a practical and effective means of delivering medication directly to the lungs, they are in high demand as a treatment modality for these conditions. The increasing number of people suffering from respiratory disorders has led to a greater focus on symptom management, averting exacerbations, and enhancing overall disease management and these are used more frequently because of their critical role in sustaining long-term symptom control and offering immediate relief which drives the growth of the market.

Restraint:

High production costs and difficulty in application

Medication noncompliance brought on by difficulties managing the condition may lead to insufficient therapy, worsening of the illness, and higher medical expenses. If patients find Dry powder inhalers difficult to handle or load, they may choose to use alternative inhaler devices like nebulizers or metered-dose inhalers (MDIs). The market share and sales of dry powder inhalers may be impacted by this change in preferences. It may be necessary for healthcare providers to devote additional time and resources to instructing patients on proper handling and loading techniques. The complexity of patient education programs may increase due to this additional training requirement, which may also raise healthcare costs thus hamper the growth of the market.

Opportunity:

Increased focus on preventive care and disease management

Healthcare systems and providers are encouraged to concentrate on early intervention strategies due to the increased emphasis on preventive care. By offering prophylactic medication to manage symptoms and stop exacerbations and they contribute significantly to the management of respiratory conditions. Patient-centric care models are becoming more and more important as the focus shifts to illness prevention and management. Dry powder inhalers complement these care models by empowering patients to actively manage their respiratory conditions because they are easy to use and appropriate for self-administration.

Threat:

Availability of raw materials with intense competition

Insufficient compliance with drug regimens, such as dry powder inhalers, may result in insufficient treatment of respiratory disorders like COPD or asthma. Reduced lung function, an increase in the frequency of exacerbations, worsening symptoms, and an increased risk of hospitalization can all be caused by incomplete or irregular dosing. Moreover, demand of patient preferences, and prescription rates may all be impacted if patients fail to comply for a variety of reasons, such as inhaler difficulties. This might result in having a smaller market share than other kinds of inhalers.

COVID-19 Impact

Demand for respiratory medications, including those given through DPIs, surged during the pandemic as a result of increased awareness of respiratory health and worries about lung health brought on by COVID-19. Patients with long-term respiratory disorders tried to get access to the drugs they needed and continue their treatment plans. There was a move toward at-home medication self-administration due to limitations on mobility and visits to medical facilities. Due to their self-administration capabilities and ease of use, DPIs have become the go-to choice for treating respiratory disorders when regular clinic visits are not feasible.

The multi dose dry powder inhalers segment is expected to be the largest during the forecast period

The multi dose dry powder inhalers segment is estimated to have a lucrative growth, as they are used to administer powdered medication directly into the lungs. They usually use a reservoir that holds multiple doses of the powdered medication, allowing patients to take multiple doses over time. They enable the device to be preloaded with multiple doses, giving patients dosage flexibility and the ability to take their recommended doses at predetermined intervals. In order to meet patient needs and enhance treatment outcomes, manufacturers in this market sector are constantly innovating, concentrating on bettering drug delivery systems, ergonomics of devices, and dose accuracy.

The digitally operated inhaler devices segment is expected to have the highest CAGR during the forecast period

The digitally operated inhaler devices segment is anticipated to witness the highest CAGR growth during the forecast period, because digitally operated inhaler devices are a new and creative segment. Digital technology in these inhalers enables improved features like data tracking, connectivity, and better patient adherence to prescription schedules. Thus, the goal of adding digital components to inhaler devices is to enhance the way respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are managed. Because digitally operated inhalers collect data on individual patient responses to treatment and inhaler usage patterns, they can support personalized medicine approaches thus boosting the growth of the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the as a result of numerous government programs and healthcare regulations targeted at enhancing respiratory health and illness management. Adoption of DPIs and other effective inhalation therapies is frequently encouraged by supportive policies. Patient adherence and management are improved by the combination of DPIs with digital technologies, such as smart inhalers that provide features like dose tracking, reminders, and connectivity. The evolution of the market is driven by this patient-centric approach.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the incidence of respiratory conditions such as asthma and COPD has been increasing, which has increased the need for efficient inhalation treatments. DPIs provide a practical and effective means of administering medicine to treat these ailments. Moreover, the market has grown as a result of ongoing innovations in drug delivery systems, formulations, and DPI designs. To increase medication adherence and efficacy, manufacturers are always working to create DPIs that are more portable, user-friendly, and efficient.

Key players in the market:

Some of the key players profiled in the Dry Powder Inhalers Market include GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A, AptarGroup, Inc., Iconovo AB, Mylan N.V, Pharmaxis, Teva Pharmaceutical Industries Limited, AstraZeneca Plc, Novartis AG, Elpen S.A, Vectura Group Plc, Beximco Pharmaceuticals Ltd, Hovione, MannKind Corporation, Sava Healthcare Ltd, 3M Company and DPI Co., Ltd.

Key Developments:

In October 2023, GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen. There is high unmet need in CHB with an estimated 300 million people living with the disease and a less than 3-7% functional cure rate with current treatment options.

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. New research reveals a nationwide focus on STEM mentoring of under-represented groups could boost individual incomes.

In October 2023, Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs

Products Covered:

• Multi Dose Dry Powder Inhalers
• Single Dose Dry Powder Inhalers

Functions Covered:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

Indications Covered:

• Pulmonary Arterial Hypertension
• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Cystic Fibrosis

End Users Covered:

• Drug Stores
• Retail Pharmacies
• Hospitals
• Online Pharmacies
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Dry Powder Inhalers Market, By Product

• 5.1 Introduction
• 5.2 Multi Dose Dry Powder Inhalers
• 5.3 Single Dose Dry Powder Inhalers

6 Global Dry Powder Inhalers Market, By Function

• 6.1 Introduction
• 6.2 Manually Operated Inhaler Devices
• 6.3 Digitally Operated Inhaler Devices

7 Global Dry Powder Inhalers Market, By Indication

• 7.1 Introduction
• 7.2 Pulmonary Arterial Hypertension
• 7.3 Chronic Obstructive Pulmonary Disease (COPD)
• 7.4 Asthma
• 7.5 Cystic Fibrosis

8 Global Dry Powder Inhalers Market, By End User

• 8.1 Introduction
• 8.2 Drug Stores
• 8.3 Retail Pharmacies
• 8.4 Hospitals
• 8.5 Online Pharmacies
• 8.6 Ambulatory Surgical Centers
• 8.7 Other End Users

9 Global Dry Powder Inhalers Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 GlaxoSmithKline Plc
• 11.2 Boehringer Ingelheim GmbH
• 11.3 Cipla Limited
• 11.4 Chiesi Farmaceutici S.p.A
• 11.5 AptarGroup, Inc.
• 11.6 Iconovo AB
• 11.7 Mylan N.V
• 11.8 Pharmaxis
• 11.9 Teva Pharmaceutical Industries Limited
• 11.10 AstraZeneca Plc
• 11.11 Novartis AG
• 11.12 Elpen S.A
• 11.13 Vectura Group Plc
• 11.14 Beximco Pharmaceuticals Ltd
• 11.15 Hovione
• 11.16 MannKind Corporation
• 11.17 Sava Healthcare Ltd
• 11.18 3M Company
• 11.19 DPI Co., Ltd.